Literature DB >> 12892843

EMD 281014, a new selective serotonin 5-HT2A receptor antagonist.

Gerd D Bartoszyk1, Christoph van Amsterdam, Henning Böttcher, Christoph A Seyfried.   

Abstract

The 5-HT2A receptor ligand 7-[4-[2-(4-fluoro-phenyl)-ethyl]-piperazine-1-carbonyl]-1H-indole-3-carbonitrile HCl (EMD 281014) selectively binds to human (h) and rat 5-HT2A receptors (IC50 values 0.35 and 1 nM, respectively; vs. 1334 nM for h5-HT2C) and inhibited 5-HT-stimulated [35S]guanosine 5'-O-3-thiotriphosphate (GTPgammaS)-accumulation in h5-HT2A transfected Chinese hamster ovary cells (IC50 9.3 nM). EMD 28014 counteracted the N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ)-induced decrease of [3H]ketanserin binding in rat frontal cortex (ID50 0.4 mg/kg p.o.) and R-(-)-1-(2,5-dimethoxy-4-iodophenyl)-aminopropane (DOI)-induced head-twitch behaviour in mice (ID50 0.01 mg/kg s.c., 0.06 mg/kg p.o.), demonstrating unique selectivity and efficacy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12892843     DOI: 10.1016/s0014-2999(03)01992-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Selective serotonin 5-HT2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys.

Authors:  Alvin V Terry; Jerry J Buccafusco; Gerd D Bartoszyk
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

2.  YKP1447, A Novel Potential Atypical Antipsychotic Agent.

Authors:  Seon Min Dong; Yong Gil Kim; Joon Heo; Mi Kyung Ji; Jeong Woo Cho; Byong Sung Kwak
Journal:  Korean J Physiol Pharmacol       Date:  2009-04-30       Impact factor: 2.016

Review 3.  5-HT2A blockade for dyskinesia and psychosis in Parkinson's disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review.

Authors:  Cynthia Kwan; Imane Frouni; Dominique Bédard; Stephen G Nuara; Jim C Gourdon; Adjia Hamadjida; Philippe Huot
Journal:  Exp Brain Res       Date:  2018-11-15       Impact factor: 1.972

4.  A spinal mechanism of action for duloxetine in a rat model of painful diabetic neuropathy.

Authors:  T Mixcoatl-Zecuatl; C G Jolivalt
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

5.  Evaluation of the effects of the mGlu2/3 antagonist LY341495 on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset.

Authors:  Stephen G Nuara; Jim C Gourdon; Philippe Huot
Journal:  Pharmacol Rep       Date:  2022-06-27       Impact factor: 3.919

6.  EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study.

Authors:  David Mamo; Ewen Sedman; Joachim Tillner; Edward M Sellers; Myroslava K Romach; Shitij Kapur
Journal:  Psychopharmacology (Berl)       Date:  2004-09       Impact factor: 4.530

Review 7.  Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.

Authors:  Adam L Halberstadt
Journal:  Behav Brain Res       Date:  2014-07-15       Impact factor: 3.332

8.  An ontogenic study of receptor mechanisms by which acute administration of low-doses of methamphetamine suppresses DOI-induced 5-HT2A-receptor mediated head-twitch response in mice.

Authors:  Yina Sun; Seetha Chebolu; Denise Henry; Sandeep Lankireddy; Nissar A Darmani
Journal:  BMC Neurosci       Date:  2022-01-04       Impact factor: 3.288

9.  Role of 5-HT2A receptor antagonists in the treatment of insomnia.

Authors:  Kimberly E Vanover; Robert E Davis
Journal:  Nat Sci Sleep       Date:  2010-07-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.